Breaking News, Collaborations & Alliances

Biotheus and Hansoh Pharma Expand Collaboration for Novel Cancer Treatment

Biotheus grants Hansoh Pharma a license to use PM1080/HS-20117 for the development of antibody-drug conjugates.

Author Image

By: Charlie Sternberg

Associate Editor

Biotheus Inc., a clinical-stage biotech company focusing on the discovery and development of biologics for oncology and inflammatory diseases, and Hansoh Pharmaceutical Group Co., Ltd., a Chinese pharmaceutical company, have agreed to further expand their strategic collaboration.   Biotheus will grant Hansoh Pharma a license to use the proprietary anti-EGFR/cMet bispecific antibody PM1080/HS-20117 independently developed by Biotheus for the development of antibody-drug conjugates products (ADC...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters